Impact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective Study

Basit Öğe Kaydı
dc.authoridAcar, İbrahim Halil/0000-0002-8657-1407
dc.authoridgulturk, emine/0000-0003-2836-6162
dc.authoridipek, yildiz/0000-0003-2952-2286
dc.authoridGuvenc, Birol/0000-0001-7641-5673
dc.authoridYikilmaz, Aysun/0000-0001-5281-5955
dc.authorid, gulden/0000-0002-7671-7628
dc.authoridEkinci, Omer/0000-0002-4636-3590
dc.contributor.authorAcar, Ibrahim Halil
dc.contributor.authorGüner, Şebnem İzmir
dc.contributor.authorAslaner Ak, Muzeyyen
dc.contributor.authorGöçer, Mesut
dc.contributor.authorÖztürk, Erman
dc.contributor.authorAtalay, Figen
dc.contributor.authorSincan, Gülden
dc.date.accessioned2024-09-11T19:53:13Z
dc.date.available2024-09-11T19:53:13Z
dc.date.issued2022
dc.departmentİstanbul Gelişim Üniversitesien_US
dc.description.abstractObjectives: Patients with hematological malignancies have a high risk of mortality from coronavirus disease 2019 (COVID-19). This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematological malignancies and to determine risk factors associated with all-cause mortality.Methods: A multicenter, observational retrospective analysis of patients with hematological malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study.Results: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematological malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p<0.001) and had more comorbidities (p<0.05). In addition, there were significantly more patients with low lymphocyte percentage (p<0.001), thrombocytopenia (p<0.001), and high CRP (p<0.001) in the non-survived patients. Age >= 65years (p=0.017), cardiac comorbidities (p=0.041), and continuation of ongoing active therapy for hematological cancer (p<0.001) were the independent risk factors for the prediction of mortality.Conclusions: In patients with hematological malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma have the highest mortality rates. Older age, cardiac diseases, and continuation of ongoing active therapy for hematological cancer are the independent risk factors for mortality in hematological malignancy patients with COVID-19.en_US
dc.identifier.doi10.4084/MJHID.2022.074
dc.identifier.issn2035-3006
dc.identifier.pmid36425152en_US
dc.identifier.scopus2-s2.0-85142275359en_US
dc.identifier.urihttps://doi.org/10.4084/MJHID.2022.074
dc.identifier.urihttps://hdl.handle.net/11363/8099
dc.identifier.volume14en_US
dc.identifier.wosWOS:000880389700001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherMattioli 1885en_US
dc.relation.ispartofMediterranean Journal of Hematology And Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240903_Gen_US
dc.subjectHematologic malignanciesen_US
dc.subjectCOVID-19 virus diseaseen_US
dc.subjectMortalityen_US
dc.titleImpact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective Studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Makale / Article
Boyut:
484.58 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu